Evidence map›Paper›PMID 27182949›Full record

ArticleGenetics2016

Determinants of Genetic Diversity of Spontaneous Drug Resistance in Bacteria.

Alejandro Couce, Alexandro Rodríguez-Rojas, Jesús Blázquez

Open access · bronzeAbstract read
In one paragraph

Article in Genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Novel Fosfomycin Resistance Mechanism inAntibiotics (Basel, Switzerland) · 2024
    Article
  5. Mutation bias and adaptation in bacteria.Microbiology (Reading, England) · 2023
    Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 3 countries.

Alejandro CouceCentro Nacional de Biotecnología, Consejo Superior de Investigaciones Cientffícas, 28049 Madrid, Spain Unité Mixte de Recherche 1137 (IAME-Institut National de la Santé et de la Recherche Médicale), 75018 Paris, France alejandro.couce@inserm.fr.
Alexandro Rodríguez-RojasCentro Nacional de Biotecnología, Consejo Superior de Investigaciones Cientffícas, 28049 Madrid, Spain Institut für Biologie, Freie Universität Berlin, 14195, Germany.
Jesús BlázquezCentro Nacional de Biotecnología, Consejo Superior de Investigaciones Cientffícas, 28049 Madrid, Spain Instituto de Biomedicina de Sevilla, 41013, Spain.
Centro Nacional de Biotecnología · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Any pathogen population sufficiently large is expected to harbor spontaneous drug-resistant mutants, often responsible for disease relapse after antibiotic therapy. It is seldom appreciated, however, that while larger populations harbor more mutants, the abundance distribution of these mutants is expected to be markedly uneven. This is because a larger population size allows early mutants to expand for longer, exacerbating their predominance in the final mutant subpopulation. Here, we investigate the extent to which this reduction in evenness can constrain the genetic diversity of spontaneous drug resistance in bacteria. Combining theory and experiments, we show that even small variations in growth rate between resistant mutants and the wild type result in orders-of-magnitude differences in genetic diversity. Indeed, only a slight fitness advantage for the mutant is enough to keep diversity low and independent of population size. These results have important clinical implications. Genetic diversity at antibiotic resistance loci can determine a population's capacity to cope with future challenges (i.e., second-line therapy). We thus revealed an unanticipated way in which the fitness effects of antibiotic resistance can affect the evolvability of pathogens surviving a drug-induced bottleneck. This insight will assist in the fight against multidrug-resistant microbes, as well as contribute to theories aimed at predicting cancer evolution.

Indexed as

Biological EvolutionAnti-Bacterial AgentsDrug Resistance, BacterialGenetic VariationGenotypeHumansModels, GeneticMutationNeoplasmsAnti-Bacterial Agentsantibiotic resistance costclonal heterogeneitygenetic diversitymutationpopulation size

Identifiers

PMID27182949
PMCPMC4937460
OpenAlexW2364672501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.